# Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects

> **NCT01866748** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 170 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2
- Healthy

## Interventions

- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** placebo
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01866748
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2014-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01866748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01866748, "Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01866748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*